Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02565758 | ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors | PHASE1 | COMPLETED | 85 | — | — | Sep 18, 2015 | Mar 25, 2019 | Apr 5, 2019 | 20 | United States, France +1 |
Collect all adverse events at each visit.
AUC (0-t) = Area under the serum concentration curve from time zero (pre-dose) to the time of the last measurable concentration.
| Arm | Type | Description |
|---|---|---|
| Arm A4 (ABBV-085) | EXPERIMENTAL | ABBV-085 administered on at 28 day cycle and enrolling at MD Anderson |
| Arm A3 (ABBV-085) | EXPERIMENTAL | ABBV-085 will be administered at every cycle (28-day cycles). |
| Name | Type | Description |
|---|---|---|
| ABBV-085 | DRUG | Administered as an intravenous infusion in 28-day dosing cycles. |
Inclusion Criteria: 1. Participants with advanced solid tumor that is not amenable to surgical resection or other approved therapeutic options. 2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2. 3. Participants must have measurable disease per Response Evaluation Criteria In...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab, V503, GARDASIL |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| AstraZeneca PLC | AZN | 1 | — | Trastuzumab deruxtecan |